Thalidomide- or Lenalidomide-based Maintenance Therapy Improves PFS in Multiple Myeloma

Share this content:
Thalidomide- or lenalidomide-based maintenance therapy improved progression-free survival and overall survival in patients with multiple myeloma.
Thalidomide- or lenalidomide-based maintenance therapy improved progression-free survival and overall survival in patients with multiple myeloma.

Thalidomide- or lenalidomide-based maintenance therapy improved progression-free survival and overall survival in patients with multiple myeloma, but also increased the risks of grade 3 to 4 adverse events, according to a study published in the Journal of the National Cancer Institute.1

The treatment of multiple myeloma has progressed dramatically with the introduction of immunomodulatory drugs (IMiDs) and proteasome inhibitors, however it remains incurable. Consolidation and maintenance therapy can possibly improve outcomes. While most trials have shown benefit of IMiD-based maintenance therapy in delaying disease progression, the question of whether it improves survival is unclear.

Therefore, investigators performed a meta-analysis to evaluate the impact of IMiDs on survival outcomes and serious adverse effects in patients with multiple myeloma. Investigators looked at 18 phase 3 randomized controlled trials including 7730 patients.

Results showed that IMiD-based maintenance therapy prolonged progression-free survival (HR, 0.62; 95% CI, 0.57 – 0.67; P < .001) but failed to provide an overall survival benefit (HR = 0.93; 95% CI, 0.85 – 1.01; P = .082).

Stratified analyses showed that thalidomide and lenalidomide provided progression-free survival benefit, but not in overall survival in transplantation and nontransplantation settings.

IMiD-based maintenance therapy was linked with a higher risk of patients developing grade 3 to 4 thromboembolism (risk ratio = 2.52; 95% CI, 1.41 – 4.52; P = .002).

RELATED: Marizomib May Be Active in Relapsed, Refractory Myeloma

Thalidomide maintenance therapy increased the risk of peripheral neuropathy, while lenalidomide maintenance therapy increased the risks of myelosuppression and second primary hematological malignancies.  

Reference

  1. Wang Y, Yang F, Shen Y, et al. Maintenance therapy with immunomodulatory drugs in multiple myeloma: a meta-analysis and systematic review. J Natl Cancer Inst. 2016;108(3):dvj342. 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters